Literature DB >> 28723426

Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era.

Sigrid Carlsson1, Hans Lilja2, Andrew Vickers3.   

Abstract

Optimizing the benefits versus harms of prostate-specific antigen screening can be achieved through stratifying screening and biopsy. This clinical consultation guide provides the scientific background and evidence-based recommendations.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2015        PMID： 28723426      PMCID： PMC5538790          DOI： 10.1016/j.euf.2015.05.001

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  23 in total

1.  Compliance with biopsy recommendations of a prostate cancer risk calculator.

Authors:  Heidi A van Vugt; Monique J Roobol; Martijn Busstra; Paul Kil; Eric H Oomens; Igle J de Jong; Chris H Bangma; Ewout W Steyerberg; Ida Korfage
Journal:  BJU Int       Date:  2011-09-20       Impact factor: 5.588

2.  Primary care physicians' use of an informed decision-making process for prostate cancer screening.

Authors:  Robert J Volk; Suzanne K Linder; Michael A Kallen; James M Galliher; Mindy S Spano; Patricia Dolan Mullen; Stephen J Spann
Journal:  Ann Fam Med       Date:  2013 Jan-Feb       Impact factor: 5.166

3.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Authors:  Michael W Drazer; Dezheng Huo; Mara A Schonberg; Aria Razmaria; Scott E Eggener
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

Review 4.  Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

Authors:  K S Louie; A Seigneurin; P Cathcart; P Sasieni
Journal:  Ann Oncol       Date:  2014-11-17       Impact factor: 32.976

5.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Authors:  Laurence Klotz; Danny Vesprini; Perakaa Sethukavalan; Vibhuti Jethava; Liying Zhang; Suneil Jain; Toshihiro Yamamoto; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

6.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Authors:  Andrew J Vickers; Angel M Cronin; Thomas Björk; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  BMJ       Date:  2010-09-14

7.  Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.

Authors:  James A Eastham; Elyn Riedel; Peter T Scardino; Moshe Shike; Martin Fleisher; Arthur Schatzkin; Elaine Lanza; Lianne Latkany; Colin B Begg
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

8.  Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.

Authors:  Emily A Vertosick; Bing Ying Poon; Andrew J Vickers
Journal:  J Urol       Date:  2014-03-15       Impact factor: 7.450

9.  Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Authors:  Elizabeth K Bancroft; Elizabeth C Page; Elena Castro; Hans Lilja; Andrew Vickers; Daniel Sjoberg; Melissa Assel; Christopher S Foster; Gillian Mitchell; Kate Drew; Lovise Mæhle; Karol Axcrona; D Gareth Evans; Barbara Bulman; Diana Eccles; Donna McBride; Christi van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Cezary Cybulski; Dominika Wokolorczyk; Christina Selkirk; Peter J Hulick; Anders Bojesen; Anne-Bine Skytte; Jimmy Lam; Louise Taylor; Rogier Oldenburg; Ruben Cremers; Gerald Verhaegh; Wendy A van Zelst-Stams; Jan C Oosterwijk; Ignacio Blanco; Monica Salinas; Jackie Cook; Derek J Rosario; Saundra Buys; Tom Conner; Margreet G Ausems; Kai-ren Ong; Jonathan Hoffman; Susan Domchek; Jacquelyn Powers; Manuel R Teixeira; Sofia Maia; William D Foulkes; Nassim Taherian; Marielle Ruijs; Apollonia T Helderman-van den Enden; Louise Izatt; Rosemarie Davidson; Muriel A Adank; Lisa Walker; Rita Schmutzler; Kathy Tucker; Judy Kirk; Shirley Hodgson; Marion Harris; Fiona Douglas; Geoffrey J Lindeman; Janez Zgajnar; Marc Tischkowitz; Virginia E Clowes; Rachel Susman; Teresa Ramón y Cajal; Nicholas Patcher; Neus Gadea; Allan Spigelman; Theo van Os; Annelie Liljegren; Lucy Side; Carole Brewer; Angela F Brady; Alan Donaldson; Vigdis Stefansdottir; Eitan Friedman; Rakefet Chen-Shtoyerman; David J Amor; Lucia Copakova; Julian Barwell; Veda N Giri; Vedang Murthy; Nicola Nicolai; Soo-Hwang Teo; Lynn Greenhalgh; Sara Strom; Alex Henderson; John McGrath; David Gallagher; Neil Aaronson; Audrey Ardern-Jones; Chris Bangma; David Dearnaley; Philandra Costello; Jorunn Eyfjord; Jeanette Rothwell; Alison Falconer; Henrik Gronberg; Freddie C Hamdy; Oskar Johannsson; Vincent Khoo; Zsofia Kote-Jarai; Jan Lubinski; Ulrika Axcrona; Jane Melia; Joanne McKinley; Anita V Mitra; Clare Moynihan; Gad Rennert; Mohnish Suri; Penny Wilson; Emma Killick; Sue Moss; Rosalind A Eeles
Journal:  Eur Urol       Date:  2014-01-15       Impact factor: 20.096

10.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Authors:  Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja
Journal:  BMJ       Date:  2013-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.